Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25922340 | 0.88 | CTDSP1 (0.64) | CTDSP1LMNAKDM4EMAPTPOLB | |
| SCHEMBL25922275 | 0.85 | TP53 (0.59) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL25922300 | 0.85 | CTDSP1 (0.61) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL24124782 | 0.84 | MAPT (0.55) | LMNATP53MAPTSMN1; SMN2POLB | |
| SCHEMBL30270587 | 0.83 | CYP1A2 (0.58) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL25921866 | 0.83 | CYP1A2 (0.58) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL25922344 | 0.81 | CYP1A2 (0.56) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL25927899 | 0.80 | CTDSP1 (0.55) | CTDSP1LMNATP53KDM4EMAPT | |
| SCHEMBL18890873 | 0.77 | MAPT (0.65) | LMNATP53MAPTSMN1; SMN2POLB | |
| SCHEMBL31411638 | 0.77 | MAPT (0.58) | LMNATP53MAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | CTDSP1 2570/4885LMNA 4265/4885TP53 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.